Exact Mass: 365.2103162
Exact Mass Matches: 365.2103162
Found 428 metabolites which its exact mass value is equals to given mass value 365.2103162,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Senkirkin
CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 178 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 168 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 158 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 148 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 138 INTERNAL_ID 138; CONFIDENCE Reference Standard (Level 1) CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 128 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 118 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 108 INTERNAL_ID 2283; CONFIDENCE Reference Standard (Level 1) CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2283
Trimethaphan
Trimethaphan is only found in individuals that have used or taken this drug. It is a nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. [PubChem]Trimethaphan is a ganglionic blocking agent prevents stimulation of postsynaptic receptors by competing with acetylcholine for these receptor sites. Additional effects may include direct peripheral vasodilation and release of histamine. Trimethaphans hypotensive effect is due to reduction in sympathetic tone and vasodilation, and is primarily postural. C - Cardiovascular system > C02 - Antihypertensives > C02B - Antiadrenergic agents, ganglion-blocking > C02BA - Sulfonium derivatives C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C66886 - Nicotinic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D005730 - Ganglionic Blockers D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002491 - Central Nervous System Agents
Brevianamide B
Brevianamide A is a mycotoxin from Penicillium brevi-compactum and some other Penicillium specie
Aegle marmelos Alkaloid C
Aegle marmelos Alkaloid C is found in fruits. Aegle marmelos Alkaloid C is an alkaloid from leaves of Aegle marmelos (bael). Alkaloid from leaves of Aegle marmelos (bael). Aegle marmelos Alkaloid C is found in fruits.
Isopentenyladenine-9-N-glucoside
Isopentenyladenine-9-N-glucoside belongs to the class of organic compounds known as glycosylamines. Glycosylamines are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether). Isopentenyladenine-9-N-glucoside is a strong basic compound (based on its pKa). Isopentenyladenine-9-N-glucoside is produced when isopentenyladenine and UDP-D-glucose react, with UDP as a byproduct. The reaction is catalyzed by UDP glycosyltransferases. Isopentenyladenine-9-N-glucoside is produced when isopentenyladenine and UDP-D-glucose react, with UDP as a byproduct. The reaction is catalyzed by UDP glycosyltransferases. [HMDB]
5-O-Desmethyldonepezil
5-O-Desmethyldonepezil is only found in individuals that have used or taken Donepezil. 5-O-Desmethyldonepezil is a metabolite of Donepezil. 5-o-desmethyldonepezil belongs to the family of Indanones. These are compounds containing an indane ring bearing a ketone group.
6-O-Desmethyldonepezil
6-O-Desmethyldonepezil is only found in individuals that have used or taken Donepezil. 6-O-Desmethyldonepezil is a metabolite of Donepezil. 6-o-desmethyldonepezil belongs to the family of Indanones. These are compounds containing an indane ring bearing a ketone group.
Nequinate
C22H23NO4 (365.16269980000004)
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent Antiprotozoan; used as a coccidiostat for poultry and rabbit
Tetradeca-7,9,11-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-7,9,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-7,9,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-7,9,11-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-7,9,11-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tetradeca-3,5,7-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-3,5,7-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-3,5,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-3,5,7-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-3,5,7-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tetradeca-8,10,12-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-8,10,12-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-8,10,12-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-8,10,12-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-8,10,12-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tetradeca-4,7,10-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-4,7,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-4,7,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-4,7,10-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-4,7,10-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tetradeca-4,6,8-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-4,6,8-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-4,6,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-4,6,8-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-4,6,8-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tetradeca-6,9,12-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-6,9,12-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-6,9,12-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-6,9,12-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-6,9,12-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tetradeca-5,7,9-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-5,7,9-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-5,7,9-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-5,7,9-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-5,7,9-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tetradeca-5,8,11-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-5,8,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-5,8,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-5,8,11-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-5,8,11-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tetradeca-2,5,8-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-2,5,8-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-2,5,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-2,5,8-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-2,5,8-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tetradeca-6,8,10-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-6,8,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-6,8,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-6,8,10-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-6,8,10-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,10Z,12E)-Tetradeca-4,10,12-trienoylcarnitine
C21H35NO4 (365.25659500000006)
(4Z,10Z,12E)-Tetradeca-4,10,12-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,10Z,12E)-tetradeca-4,10,12-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,10Z,12E)-Tetradeca-4,10,12-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (4Z,10Z,12E)-Tetradeca-4,10,12-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tetradeca-3,6,9-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-3,6,9-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-3,6,9-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-3,6,9-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-3,6,9-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tetradeca-2,4,6-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-2,4,6-trienoylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-2,4,6-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-2,4,6-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-2,4,6-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Arachidonyl-2-chloroethylamide
C22H36ClNO (365.24852760000005)
Caroverine
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Florbenazine
2-Chloro-N-icosa-5,8,11,14-tetraenylacetamide
C22H36ClNO (365.24852760000005)
Timegadine
C20H23N5S (365.16740780000003)
Nafadotride
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists
2-(3,4-Diguanidinobutanoylamino)-3-(4-hydroxyphenyl)propionic acid
C15H23N7O4 (365.18114380000003)
3alpha-(O-methylitaconyl)-6beta-angeloyloxytropane|Schizanthine G
1-methylzeatine riboside|6-(4-hydroxy-1,3-dimethylbut-trans-2-enylamino)-9-beta-D-ribofuranosylpurine
6-(4-Methoxyphenyl)-7-(3,4-dimethoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizine
Oxime-(3alpha,5alpha,20S)-3,20,21-Trihydroxypregnan-11-one
C21H35NO4 (365.25659500000006)
5alpha,12-dihydroxy-1-tremulen-11-yl 2(S)-pyroglutamate
(3Z)-8a-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methylidene}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione|brevianamide Q
3alpha-(O-methylitaconyl)-6beta-senecioyloxytropane
3alpha-(O-methylmesaconyl)-6beta-senecioyloxytropane
N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide
C22H36ClNO (365.24852760000005)
Renardin
Senkirkine is a macrolide. Senkirkine is a natural product found in Tussilago farfara, Senecio gallicus, and other organisms with data available. See also: Petasites hybridus root (part of); Tussilago farfara flower (part of); Tussilago farfara leaf (part of).
Isopentenyl-Adenine-9-glucoside
Acquisition and generation of the data is financially supported by the Max-Planck-Society
Isopentenyl-Adenine-7-glucoside
Acquisition and generation of the data is financially supported by the Max-Planck-Society
isopentenyl-Adenine-7-glucoside-[d6]
Acquisition and generation of the data is financially supported by the Max-Planck-Society
isopentenyl-Adenine-9-glucoside-[d6]
Acquisition and generation of the data is financially supported by the Max-Planck-Society
(S)-3-((6-hydroxy-2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)methyl)-2,3,6,7-tetrahydropyrrolo[1,2-a]pyrazine-1,4-dione
JWH 250 N-(5-carboxyxypentyl) metabolite
C22H23NO4 (365.16269980000004)
5-O-Desmethyldonepezil
A member of the class of piperidines that is donepezil in which the 5-methoxy group has been demethylated to the corresponding hydroxy derivative. It is metabolite of donepezil, a drug used in the treatment of dementia.
6-O-Desmethyldonepezil
Brevianamide B
Statyl
C22H23NO4 (365.16269980000004)
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
Aegle marmelos Alkaloid C
1-(Dimethylamino)-3-(2-(3-methoxyphenethyl)phenoxy)propan-2-ol hydrochloride
C20H28ClNO3 (365.17576080000003)
Basic Violet 2
C22H24ClN3 (365.16586540000003)
D004396 - Coloring Agents > D012394 - Rosaniline Dyes
potassium,dodecane-1-thiol,prop-2-enenitrile,prop-2-enoate
Timegadine
C20H23N5S (365.16740780000003)
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
3-N-BOC-AMINO-1-[2-AMINO-1-(2,5-DIMETHOXY-PHENYL)-ETHYL]-PYRROLIDINE
C19H31N3O4 (365.23144460000003)
3-N-BOC-AMINO-1-[2-AMINO-1-(3,4-DIMETHOXY-PHENYL)-ETHYL]-PYRROLIDINE
C19H31N3O4 (365.23144460000003)
tert-butyl 1-(4-(2-phenylacetyl)phenyl)cyclobutylcarbamate
2-[bis(2-hydroxyethyl)amino]ethanol,2-butoxyethanol,phosphoric acid
Urea, N-[2-[(3-cyano-6,8-dimethyl-2-quinolinyl)amino]ethyl]-N-cyclohexyl- (9CI)
A 77636 hydrochloride
C20H28ClNO3 (365.17576080000003)
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists A-77636 hydrochloride is a potent, orally active, selective and long acting dopamine D1 receptor agonist (pKi=7.40; Ki=39.8 nM) with antiparkinsonian activity. A-77636 hydrochloride is functionally inactive at dopamine D2 receptor[1][2].
(1S,2R)-1-[(3,5-DI-TERT-BUTYL-2-HYDROXYBENZYLIDENE)AMINO]-2-INDANOL
(s)-tert-butyl 1-(tert-butyldimethylsilyloxy)-3-phenylpropan-2-ylcarbamate
C20H35NO3Si (365.23860800000006)
Micafungin Side Chain Methyl Ester
C22H23NO4 (365.16269980000004)
(1R,2S)-2-[N-BENZYL-N-(MESITYLENESULFONYL)AMINO]-1-PHENYL-1-PROPANOL
C22H23NO4 (365.16269980000004)
(1S,2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)cyclohexane-1-carboxylic acid
C22H23NO4 (365.16269980000004)
(1S,2R)-2-[N-BENZYL-N-(MESITYLENESULFONYL)AMINO]-1-PHENYL-1-PROPANOL
C22H23NO4 (365.16269980000004)
(3R,4R,5S)-4-(4-HYDROXYPHENYL)-5-((TRIISOPROPYLSILYL)OXY)PIPERIDIN-3-OL
C20H35NO3Si (365.23860800000006)
2-[1-(9H-fluoren-9-ylmethoxycarbonylamino)cyclopentyl]acetic acid
C22H23NO4 (365.16269980000004)
3-Fluoro-4-cyanophenyl trans-4-(4-n-propylcyclohexyl)-benzoate
3-[4-(Hexyloxy)phenyl]-3-({[(2-methyl-2-propanyl)oxy]carbonyl}ami no)propanoic acid
(1R,2R)-FMOC-2-AMINOCYCLOHEXANE CARBOXYLIC ACID
C22H23NO4 (365.16269980000004)
1-(4-[PHENYLAZO]PHENYLAZO)-2-METHYLAMINONAPHTHALENE
METHYL4-((5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)CARBAMOYL)BENZOATE
(1R,2S)-1-[(3,5-DI-TERT-BUTYL-2-HYDROXYBENZYLIDENE)AMINO]-2-INDANOL
[4-[2-(diethylamino)ethoxy]phenyl]-(2-ethyl-1-benzofuran-3-yl)methanone
1-O-tert-butyl 4-O-ethyl 4-[(4-fluorophenyl)methyl]piperidine-1,4-dicarboxylate
C20H28FNO4 (365.20022600000004)
1,3,3-trimethyl-2-[[methyl(p-tolyl)hydrazono]methyl]-3H-indolium acetate
1-(Fmoc-amino)cyclohexanecarboxylic acid
C22H23NO4 (365.16269980000004)
(αS)-α-[[(1R)-2-Hydroxy-1-phenylethyl]aMino]-tricyclo[3.3.1.1(3,7)]decane-1-acetic acid hydrochloride
C20H28ClNO3 (365.17576080000003)
{3-[2-(Dimethylamino)ethyl]-5-[(pyrrolidine-1-yl)sulfonylmethyl]-1H-indol-1-yl}Methanol
(2R,4S)-4-([1,1-Biphenyl]-4-ylmethyl)-2-methyl-4-(2,5-dioxopyrrolidin-1-yl)butanoic acid
C22H23NO4 (365.16269980000004)
3-fmoc-amino-cyclohexanecarboxylic acid
C22H23NO4 (365.16269980000004)
(1S,2R)-FMOC-2-AMINOCYCLOHEXANE CARBOXYLIC ACID
C22H23NO4 (365.16269980000004)
2-Methoxy-5-[[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]benzoic acid methyl ester
(R)-2-(1-(((9H-Fluoren-9-yl)methoxy)carbonyl)piperidin-2-yl)
C22H23NO4 (365.16269980000004)
(R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-cyclobutyl
C22H23NO4 (365.16269980000004)
5,6-bis[4-(dimethylamino)phenyl]-2-methyl-1,2,4-triazine-3-thione
C20H23N5S (365.16740780000003)
4-[(E)-(5-Piperidin-1-ylfuran-2-yl)methylideneamino]spiro[4-azatricyclo[5.2.1.02,6]dec-8-ene-10,1-cyclopropane]-3,5-dione
5-[2-(1-Azepanyl)-2-oxoethyl]-1-(4-methylphenyl)-4-pyrazolo[3,4-d]pyrimidinone
1-[[4-(2,4,6-Trimethylphenyl)-1-piperazinyl]sulfonyl]azepane
2-methyl-N-[2-[1-[2-(4-methylphenoxy)ethyl]-2-benzimidazolyl]ethyl]propanamide
JWH 250 N-pentanoic acid metabolite
C22H23NO4 (365.16269980000004)
2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide
HG9A-9, Nonanoyl-N-hydroxyethylglucamide
C17H35NO7 (365.24134000000004)
Caroverine
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
3-cyclohexyl-N-{3-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]phenyl}propanamide
2-(5-Chloro-2-morpholin-4-ylanilino)-1-(3-methylpiperidin-1-yl)propan-1-one
C19H28ClN3O2 (365.18699380000004)
7-(alpha-D-glucosyl)-N(6)-isopentenyladenine
A glucosyl-N(6)-isopentenyladenine in which the glucosyl moiety is in the pyranose form, has alpha-D-configuration and is located at position N-7.
(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-[hydroxy(methyl)phosphoryl]butanoyl]amino]propanoyl]amino]-4-methylpentanoic acid
(2S,9S)-10,10-dimethylspiro[1H-indole-2,11-3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane]-2,3,14-trione
2-Chloro-N-icosa-5,8,11,14-tetraenylacetamide
C22H36ClNO (365.24852760000005)
Arachidonyl-2-(chloroethyl-d4)amide
C22H36ClNO (365.24852760000005)
Tetradeca-7,9,11-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-4,7,10-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-6,9,12-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-5,8,11-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-6,8,10-trienoylcarnitine
C21H35NO4 (365.25659500000006)
Tetradeca-8,10,12-trienoylcarnitine
C21H35NO4 (365.25659500000006)
(4Z,10Z,12E)-Tetradeca-4,10,12-trienoylcarnitine
C21H35NO4 (365.25659500000006)
N-butyl-N-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-2-pyridinecarboxamide
N-(2-aminophenyl)-4-hydroxy-2-oxo-1-pentyl-3-quinolinecarboxamide
7-(4-Ethoxyphenyl)-5-(3-methoxyphenyl)-1,5,6,7-tetrahydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine
N-[2-(4-Isobutyryl-piperazin-1-yl)-phenyl]-4-methyl-benzamide
N-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-3-(2-methylphenoxy)propanamide
2-[[3-Acetyl-1-[4-(dimethylamino)phenyl]-2-methyl-5-indolyl]oxy]acetamide
4-hydroxy-2-oxo-1-pentyl-N-(pyridin-2-ylmethyl)-1,2-dihydroquinoline-3-carboxamide
4-[(2E)-2-(3-allyl-2-hydroxybenzylidene)hydrazino]-N-(4-methylphenyl)-4-oxobutanamide
18-hydroxycarbocyclic thromboxane A2(1-)
C21H33O5- (365.23278680000004)
[1-[(1-Ethyl-4-pyrazolyl)methyl]-3-piperidinyl]-[3-(trifluoromethyl)phenyl]methanone
N-(2-cyclohexylidene-1-phenylethyl)-1,1-diphenylmethanimine
3-[4-[(1R,5S)-3-(phenylmethyl)-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile
(2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide
(1S,9R,10R,11R)-11-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-10-(hydroxymethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(1S,5R)-7-[4-(4-methoxyphenyl)phenyl]-N-propyl-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide
[(2R,3S,4S)-4-[(propan-2-ylamino)methyl]-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridin-3-ylmethyl)azetidin-2-yl]methanol
(2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide
(1R,9S,10S,11S)-11-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-10-(hydroxymethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
beta-D-Tyvp-(1->3)-beta-D-GalpNAc-OMe
C15H27NO9 (365.16857319999997)
(2S)-2-[[(1S)-1-carboxy-2-phenylethyl]carbamoylamino]-5-(diaminomethylideneamino)pentanoic acid
6-Hydroxy-3,4-dihydro-2,5,7,8-tetramethyl-2-[2-[(3-isopropylamino-2-hydroxypropyl)oxy]ethyl]-2H-1-benzopyran
C21H35NO4 (365.25659500000006)
TRIMETHAPHAN
C - Cardiovascular system > C02 - Antihypertensives > C02B - Antiadrenergic agents, ganglion-blocking > C02BA - Sulfonium derivatives C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C66886 - Nicotinic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D005730 - Ganglionic Blockers D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002491 - Central Nervous System Agents
Nequinate
C22H23NO4 (365.16269980000004)
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
(2S,3R,4E)-2-aminoheptadec-4-ene-1,3-diol-1-phosphate
AcCa(14:3)
C21H35NO4 (365.25659500000006)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
5'-O-TBDMS-dA
5'-O-TBDMS-dA is a modified nucleoside and can be used to synthesize DNA or RNA.
(8as)-6-(3,4-dimethoxyphenyl)-7-(4-methoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizine
(20r,21s)-5,11-dimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene-10,21-diol
C22H23NO4 (365.16269980000004)
8-({4-methoxyfuro[2,3-b]quinolin-7-yl}oxy)-2,6-dimethylocta-2,5-dien-4-one
C22H23NO4 (365.16269980000004)
1-methyl (1r,3r,5s,6r)-8-methyl-6-[(3-methylbut-2-enoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2z)-2-methylbut-2-enedioate
6-(3,4-dimethoxyphenyl)-7-(4-methoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizine
(3z,8ar)-1,8a-dihydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6h,7h,8h-pyrrolo[1,2-a]pyrazin-4-one
(2s)-2-{[(3r)-3,4-dicarbamimidamido-1-hydroxybutylidene]amino}-3-(4-hydroxyphenyl)propanoic acid
C15H23N7O4 (365.18114380000003)
5,11-dimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene-10,21-diol
C22H23NO4 (365.16269980000004)
1-methyl (1r,3r,5s,6r)-8-methyl-6-[(3-methylbut-2-enoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl 2-methylidenebutanedioate
5,11-dimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene-6,10-diol
C22H23NO4 (365.16269980000004)
1-methyl (1r,3r,5s,6r)-8-methyl-6-{[(2e)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enedioate
(1r,4e,6s,7r,11z)-4-ethylidene-7-hydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
1-methyl (1r,3r,5s,6r)-8-methyl-6-[(3-methylbut-2-enoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enedioate
(2s,3s,4r,5s,6r)-2-(hydroxymethyl)-6-{6-[(3-methylbut-2-en-1-yl)amino]purin-9-yl}oxane-3,4,5-triol
(7s)-6',7'-dimethoxy-2'-methyl-6-methylidene-2,3',4',8-tetrahydrospiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinoline]
C22H23NO4 (365.16269980000004)
11α-hydroxy-acetylfawcettine
{"Ingredient_id": "HBIN000348","Ingredient_name": "11\u03b1-hydroxy-acetylfawcettine","Alias": "NA","Ingredient_formula": "C20H31NO5","Ingredient_Smile": "CC1CC23C4CCCN2CCC(C3C(C1OC(=O)C)CC4OC(=O)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "38581","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(20s,21s)-10,11-dimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene-5,21-diol
C22H23NO4 (365.16269980000004)
1-methyl (1s,3s,5r,6s)-8-methyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enedioate
1-methyl 8-methyl-6-[(2-methylbut-2-enoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl 2-methylidenebutanedioate
(1r,4z,6s,7r,11z)-4-ethylidene-7-hydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
2-hydroxy-2-{[4-(1-hydroxyocta-2,4-dien-1-ylidene)-1-methyl-3,5-dioxopyrrolidin-2-yl]methyl}-3-methylbutanoic acid
(2r,3r,4s,5r)-2-(6-{[(2r,3e)-5-hydroxy-4-methylpent-3-en-2-yl]amino}purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(1r,4z,6r,7s,11z)-4-ethylidene-7-hydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
(1r,2r,4as,8s,8as)-8-[(2r,5s)-5-chloro-2,6,6-trimethyloxan-2-yl]-1-isocyano-2-methyl-5-methylidene-octahydronaphthalen-2-ol
(5e)-8-({4-methoxyfuro[2,3-b]quinolin-7-yl}oxy)-2,6-dimethylocta-2,5-dien-4-one
C22H23NO4 (365.16269980000004)
8-({4-methoxyfuro[2,3-b]quinolin-7-yl}oxy)-2,6-dimethylocta-2,6-dien-4-one
C22H23NO4 (365.16269980000004)
(2e,4e,6e)-7-{10-[(1e,3e)-4-(c-hydroxycarbonimidoyl)buta-1,3-dien-1-yl]-3-oxatricyclo[5.3.1.0⁴,¹¹]undeca-5,8-dien-2-yl}hepta-2,4,6-trienoic acid
C22H23NO4 (365.16269980000004)
(1's,2r,3'r,7's)-13'-hydroxy-4',4'-dimethyl-1h-9',14'-diazaspiro[indole-2,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-ene-3,8'-dione
1-methyl 8-methyl-6-[(2-methylbut-2-enoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl 2-methylbut-2-enedioate
(20s,21r)-5,11-dimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene-10,21-diol
C22H23NO4 (365.16269980000004)
(1's,3s,3'r,7's)-2,13'-dihydroxy-4',4'-dimethyl-9',14'-diazaspiro[indole-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-en-8'-one
(1s,4z,6r,7r)-4-ethylidene-7-hydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
13'-hydroxy-4',4'-dimethyl-1h-9',14'-diazaspiro[indole-2,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-ene-3,8'-dione
(20s)-5,11-dimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene-6,10-diol
C22H23NO4 (365.16269980000004)
1-methyl (1s,3s,5r,6s)-8-methyl-6-{[(2e)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-3-yl 2-methylidenebutanedioate
(5z)-8-({4-methoxyfuro[2,3-b]quinolin-7-yl}oxy)-2,6-dimethylocta-2,5-dien-4-one
C22H23NO4 (365.16269980000004)
4-({[(3r,3ar,4s,6ar,8s,9ar,9bs)-4,8-dihydroxy-6,9-dimethylidene-2-oxo-octahydro-3h-azuleno[4,5-b]furan-3-yl]methyl}amino)butanoic acid
(2s,3's)-13'-hydroxy-4',4'-dimethyl-1h-9',14'-diazaspiro[indole-2,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-ene-3,8'-dione
6-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate
C22H23NO4 (365.16269980000004)
1-methyl (1r,3r,5s,6r)-8-methyl-6-{[(2e)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-3-yl 2-methylidenebutanedioate
4-ethylidene-7-hydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
2-[(1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-3-methylbutyl)-c-hydroxycarbonimidoyl]cyclopropane-1-carboxylic acid
(4z,11z)-4-ethylidene-7-hydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
(2e)-n-[(2s)-2-methoxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl]-3-phenylprop-2-enimidic acid
1,8a-dihydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6h,7h,8h-pyrrolo[1,2-a]pyrazin-4-one
2-[(3,4-dicarbamimidamido-1-hydroxybutylidene)amino]-3-(4-hydroxyphenyl)propanoic acid
C15H23N7O4 (365.18114380000003)
1-methyl (1r,3r,5s,6r)-8-methyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-3-yl (2z)-2-methylbut-2-enedioate
2-[(1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-2-methylbutyl)-c-hydroxycarbonimidoyl]cyclopropane-1-carboxylic acid
7-hydroxy-5-methoxy-8-(1-methylpiperidin-2-yl)-2-phenylchromen-4-one
C22H23NO4 (365.16269980000004)
1-methyl (1s,3s,5r,6s)-8-methyl-6-{[(2e)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enedioate
2-hydroxy-2-{[(2r)-4-(1-hydroxyocta-2,4-dien-1-ylidene)-1-methyl-3,5-dioxopyrrolidin-2-yl]methyl}-3-methylbutanoic acid
(6s,6ar,10r,10as)-2-methoxy-10-methyl-4-phenyl-6-[(1e)-prop-1-en-1-yl]-6h,6ah,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-one
(1r,4s,7s,11z)-4-ethyl-7-hydroxy-7,14-dimethyl-6-methylidene-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
(8ar)-7-(3,4-dimethoxyphenyl)-6-(4-methoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizine
(10s)-9-hydroxy-10-isopropyl-7-{[(2e)-3-oxo-1h-indol-2-ylidene]methyl}-5,8-diazatricyclo[5.2.2.0¹,⁵]undec-8-en-6-one
(2s)-2-hydroxy-2-{[(2s,4z)-4-[(2e,4e)-1-hydroxyocta-2,4-dien-1-ylidene]-1-methyl-3,5-dioxopyrrolidin-2-yl]methyl}-3-methylbutanoic acid
7-(3,4-dimethoxyphenyl)-6-(4-methoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizine
(1s,2s)-2-{[(1s)-1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-3-methylbutyl]-c-hydroxycarbonimidoyl}cyclopropane-1-carboxylic acid
2-methoxy-10-methyl-4-phenyl-6-[(1e)-prop-1-en-1-yl]-6h,6ah,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-one
6-methyl-1-{[3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl]methyl}-9h-carbazole-2,7-diol
n-[(1r,4r,4as,8ar)-4-[6-(2-chloropropan-2-yl)-5,6-dihydro-2h-pyran-3-yl]-1,6-dimethyl-3,4,4a,7,8,8a-hexahydro-2h-naphthalen-1-yl]carboximidic acid
1-methyl (1s,3s,5r,6s)-8-methyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-3-yl 2-methylidenebutanedioate
4-ethyl-7-hydroxy-7,14-dimethyl-6-methylidene-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
6',7'-dimethoxy-2'-methyl-6-methylidene-2,3',4',8-tetrahydrospiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinoline]
C22H23NO4 (365.16269980000004)
(1r,7s)-9-hydroxy-11-isopropyl-7-{[(2z)-3-oxo-1h-indol-2-ylidene]methyl}-5,8-diazatricyclo[5.2.2.0¹,⁵]undec-8-en-6-one
1-methyl (1r,3r,5s,6r)-8-methyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enedioate
1-methyl (3r,6r)-8-methyl-6-{[(2e)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-3-yl 2-methylidenebutanedioate
2-{[2-({2-amino-1-hydroxy-4-[hydroxy(methyl)phosphoryl]butylidene}amino)-1-hydroxypropylidene]amino}-4-methylpentanoic acid
(6e)-8-({4-methoxyfuro[2,3-b]quinolin-7-yl}oxy)-2,6-dimethylocta-2,6-dien-4-one
C22H23NO4 (365.16269980000004)
[7-hydroxy-5-(hydroxymethyl)-2,2,8-trimethyl-3,5,6,7,8,8a-hexahydro-1h-azulen-4-yl]methyl 5-hydroxy-3,4-dihydro-2h-pyrrole-2-carboxylate
1-methyl 8-methyl-6-[(3-methylbut-2-enoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl 2-methylbut-2-enedioate
7-[10-(4-carbamoylbuta-1,3-dien-1-yl)-3-oxatricyclo[5.3.1.0⁴,¹¹]undeca-5,8-dien-2-yl]hepta-2,4,6-trienoic acid
C22H23NO4 (365.16269980000004)
(20s)-6,11-dimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene-5,10-diol
C22H23NO4 (365.16269980000004)
(1s,4e,6r,7r)-4-ethylidene-7-hydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
10,11-dimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene-5,21-diol
C22H23NO4 (365.16269980000004)
2-{6-[(5-hydroxy-4-methylpent-3-en-2-yl)amino]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol
2,13'-dihydroxy-4',4'-dimethyl-9',14'-diazaspiro[indole-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-en-8'-one
(20s,21s)-5,11-dimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene-10,21-diol
C22H23NO4 (365.16269980000004)
(1s,2s)-2-{[(1s,2s)-1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-2-methylbutyl]-c-hydroxycarbonimidoyl}cyclopropane-1-carboxylic acid
(2s)-2-{[(2s)-2-{[(2s)-2-amino-1-hydroxy-4-[hydroxy(methyl)phosphoryl]butylidene]amino}-1-hydroxypropylidene]amino}-4-methylpentanoic acid
2-methoxy-10-methyl-4-phenyl-6-(prop-1-en-1-yl)-6h,6ah,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-one
[(5r,7r,8s,8ar)-7-hydroxy-5-(hydroxymethyl)-2,2,8-trimethyl-3,5,6,7,8,8a-hexahydro-1h-azulen-4-yl]methyl (2r)-5-hydroxy-3,4-dihydro-2h-pyrrole-2-carboxylate
(1r,4z,6r,7r)-4-ethylidene-7-hydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
(1'r,3s,3'r,7'r)-2,13'-dihydroxy-4',4'-dimethyl-9',14'-diazaspiro[indole-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-en-8'-one
1-methyl (1s,3r,5s)-8-methyl-6-{[(2e)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-3-yl 2-methylidenebutanedioate
(3z)-1,8a-dihydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6h,7h,8h-pyrrolo[1,2-a]pyrazin-4-one
1-methyl 8-methyl-6-[(3-methylbut-2-enoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl 2-methylidenebutanedioate
n-(2-methoxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)-3-phenylprop-2-enimidic acid
(1r,4e,6r,7r,11z)-4-ethylidene-7-hydroxy-6,7,14-trimethyl-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-ene-3,8,17-trione
(1r,3r,5s,6r)-6-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate
C22H23NO4 (365.16269980000004)
(2s)-2-hydroxy-2-{[(2s)-4-(1-hydroxyocta-2,4-dien-1-ylidene)-1-methyl-3,5-dioxopyrrolidin-2-yl]methyl}-3-methylbutanoic acid
6-methyl-1-{[(2s,3s)-3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl]methyl}-9h-carbazole-2,7-diol
2-hydroxy-2-({5-hydroxy-1-methyl-4-[(2e,4e)-octa-2,4-dienoyl]-3-oxo-2h-pyrrol-2-yl}methyl)-3-methylbutanoic acid
(1r,2r,4as,8s)-8-[(2r,5s)-5-chloro-2,6,6-trimethyloxan-2-yl]-1-isocyano-2-methyl-5-methylidene-octahydronaphthalen-2-ol
6,11-dimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaene-5,10-diol
C22H23NO4 (365.16269980000004)